Page last updated: 2024-08-24

atorvastatin and Obesity

atorvastatin has been researched along with Obesity in 67 studies

Research

Studies (67)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's24 (35.82)29.6817
2010's31 (46.27)24.3611
2020's12 (17.91)2.80

Authors

AuthorsStudies
Bao, L; Liao, M; Liu, C; Liu, H; Liu, S; Wang, J; Wang, K; Wang, L; Wang, W; Wang, Y; Zhang, J; Zheng, Z; Zhou, N1
Chen, Z; Dai, G; Fan, W; Ma, D; Mo, W; Pan, J; Wu, G; Zhang, X1
Banerjee, S; Biswas, S; Chanda, J; Kar, A; Mukherjee, PK; Tiwari, A; Ulrich-Merzenich, G1
Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG1
Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI1
Chatsudthipong, V; Cherngwelling, R; Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Pongchaidecha, A; Swe, MT; Thongnak, L1
Carvalho, D; Rodrigues, E; Saavedra, A1
Devasani, K; Kaul, R; Majumdar, A1
Amput, P; Arunsak, B; Chattipakorn, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkum, T; Kerdphoo, S; Palee, S; Pratchayasakul, W; Thonusin, C; Tosukhowong, T1
Amput, P; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Palee, S; Pratchayasakul, W1
Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G1
Christiansen, LB; Ciborowski, M; Desler, C; Dohlmann, TL; Kretowski, A; Larsen, S; Ludvigsen, TP; Martinussen, T; Olsen, LH; Orlando, P; Parfieniuk, E; Szczerbinski, L; Tiano, L1
Abdel-Gabbar, M; Anwar, S; El-Zanaty, AM; Esmail, M; Kandeil, M1
Cheung, LK; Chow, DS; El-Zailik, A; Sherman, V; Wang, Y1
Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL1
Huang, D; Liu, H; Niu, T; Wang, K; Yang, J1
Bochar, O; Bondarenko, O; Karpyshyn, N; Maksymets, T; Sklyarov, Y; Sorochka, M1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H1
Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP1
Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C1
Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A1
Chen, ZY; Gao, LH; Lei, L; Li, CN; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ1
Bochar, OM1
Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L1
Capel, F; Chabrier, G; Cynober, L; de Bandt, JP; Durand, C; Jouve, C; Le Plenier, S; Moinard, C; Morio, B; Pitois, E; Rigaudière, JP1
Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D1
Barwari, T; Bonora, E; Fernández-Hernando, C; Goedeke, L; Hughes, AD; Kaudewitz, D; Kiechl, S; Mayr, M; Moschen, AR; Ramírez, CM; Rotllan, N; Santer, P; Skroblin, P; Tilg, H; Whitehead, M; Willeit, J; Willeit, P; Yin, X; Zampetaki, A1
Bjorndahl, TC; Caplice, NM; Fitzgerald, GF; London, LE; Mandal, R; Murphy, K; Ross, RP; Ryan, PM; Shanahan, F; Stanton, C; Wishart, DS1
Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; Turzyniecka, M; Walter, L; Wild, SH1
Davy, KP; Dengo, AL; Orr, JS; Rivero, JM1
Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM1
Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N1
Acharjee, S; Cannon, CP1
Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A1
Wilke, RA1
An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN1
Hassanian, MA; Samy, W1
Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K1
Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J1
El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A1
Gracia-Sancho, J1
Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N1
Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV1
Andersson, TB; Asberg, A; Bremer, S; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Molden, E; Sandbu, R; Skottheim, IB; Ulvestad, M1
Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF3
Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF1
Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ1
Baykan, M; Eminagaoglu, S; Gökçe, M; Orem, A; Orem, C; Uydu, HA; Yilmaz, R1
Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M1
Moreno Sánchez, D1
Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K1
Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T1
Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC1
Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF1
Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A1
Nesto, RW; Singh, PP1
Kulbertus, H1
Das, S; Gidding, SS; Mitchell, D; Zhang, S1
Barrett, PH; Chan, DC; Hegele, RA; van Bockxmeer, FM; Wang, J; Watts, GF1
De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C1
Goldstein, MR; Mascitelli, L; Pezzetta, F1
Mertens, A; Muls, E; Vansant, G1
Barrett, PH; Chan, DC; James, AP; Mamo, JC; Martins, IJ; Mori, TA; Redgrave, TG; Watts, GF1
Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Watts, GF1

Reviews

3 review(s) available for atorvastatin and Obesity

ArticleYear
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:3

    Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States

2010
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:3

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome

2011
[Medical management of primary nonalcoholic fatty liver disease].
    Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3

    Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone

2005

Trials

21 trial(s) available for atorvastatin and Obesity

ArticleYear
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
    Lipids in health and disease, 2013, Jul-16, Volume: 12

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult

2013
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
    Diabetes & vascular disease research, 2014, Volume: 11, Issue:1

    Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors

2014
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

    Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides

2014
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2014, Volume: 67, Issue:2 Pt 2

    Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides

2014
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment.
    Diabetes, 2009, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Aged; Atorvastatin; Biological Transport; Blood Pressure; Double-Blind Method; Energy Metabolism; Exercise Test; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Obesity; Pyrroles

2009
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:4

    Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors

2009
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2011, Volume: 12, Issue:2

    Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides

2011
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
    Atherosclerosis, 2012, Volume: 220, Issue:2

    Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles

2012
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
    Diabetes, 2002, Volume: 51, Issue:8

    Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles

2002
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Diabetes, 2003, Volume: 52, Issue:3

    Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides

2003
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
    Atherosclerosis, 2004, Volume: 174, Issue:1

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome

2004
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Metabolism: clinical and experimental, 2005, Volume: 54, Issue:8

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior

2005
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
    The American journal of cardiology, 2006, Jun-01, Volume: 97, Issue:11

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors

2006
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
    The American journal of clinical nutrition, 2006, Volume: 84, Issue:1

    Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome

2006
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:10

    Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha

2006
Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
    Clinical endocrinology, 2008, Volume: 69, Issue:1

    Topics: Adult; Anti-Obesity Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, VLDL; Drug Resistance; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Pyrroles; Treatment Outcome

2008
The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
    Acta cardiologica, 2001, Volume: 56, Issue:3

    Topics: Adult; Apolipoprotein E3; Apolipoproteins E; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Double-Blind Method; Energy Intake; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Obesity; Polymerase Chain Reaction; Postprandial Period; Pyrroles; Triglycerides

2001
Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
    Journal of lipid research, 2002, Volume: 43, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Body Mass Index; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cholesterol; Chylomicron Remnants; Chylomicrons; Double-Blind Method; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Obesity; Placebos; Pyrroles; Time Factors; Triglycerides; Viscera

2002
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:5

    Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Viscera

2002
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
    Clinical chemistry, 2002, Volume: 48, Issue:6 Pt 1

    Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Colorimetry; Cross-Sectional Studies; Enzyme Inhibitors; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Immunoassay; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tumor Necrosis Factor-alpha

2002
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
    European journal of clinical investigation, 2002, Volume: 32, Issue:6

    Topics: Atorvastatin; Diet; Double-Blind Method; Drug Synergism; Exercise; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Obesity; Placebos; Pyrroles; Risk Factors

2002

Other Studies

43 other study(ies) available for atorvastatin and Obesity

ArticleYear
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
    Journal of medicinal chemistry, 2018, 04-26, Volume: 61, Issue:8

    Topics: alpha-Glucosidases; Animals; Anti-Obesity Agents; Drug Stability; Fatty Liver; Female; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Metabolic Syndrome; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Rats, Sprague-Dawley; Swine; Terpenes

2018
N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells.
    Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:5

    Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Atorvastatin; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Obesity; RNA, Messenger; Vascular Cell Adhesion Molecule-1

2022
Combining LC-MS/MS profiles with network pharmacology to predict molecular mechanisms of the hyperlipidemic activity of Lagenaria siceraria stand.
    Journal of ethnopharmacology, 2023, Jan-10, Volume: 300

    Topics: Animals; Atorvastatin; Chromatography, Liquid; Cucurbita; Flavonoids; Glycosides; Hesperidin; Hyperlipidemias; Hypertension; Insulins; Network Pharmacology; Obesity; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Tandem Mass Spectrometry

2023
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
    Drug safety, 2022, Volume: 45, Issue:12

    Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male; Metformin; Obesity; Phentermine; Pregnancy; Topiramate

2022
[Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?]
    Kardiologiia, 2023, Nov-08, Volume: 63, Issue:10

    Topics: Atorvastatin; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Obesity; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left

2023
Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 06-01, Volume: 1866, Issue:6

    Topics: Acute Kidney Injury; Animals; Antioxidants; Atorvastatin; Diet, High-Fat; Humans; Inflammation; Insulin; Insulin Resistance; Kidney; Lipid Metabolism; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar

2020
[Dyslipidemia Secondary to Hypothyroidism and Cholestasis].
    Acta medica portuguesa, 2020, Mar-02, Volume: 33, Issue:3

    Topics: Atorvastatin; Autoimmune Diseases; Cholestasis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Liver Cirrhosis, Biliary; Middle Aged; Obesity; Thyroxine; Withholding Treatment

2020
Supplementation of pyrroloquinoline quinone with atorvastatin augments mitochondrial biogenesis and attenuates low grade inflammation in obese rats.
    European journal of pharmacology, 2020, Aug-15, Volume: 881

    Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Blood Glucose; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Liver; Male; Mitochondria, Liver; Obesity; Organelle Biogenesis; PQQ Cofactor; Rats, Sprague-Dawley

2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats.
    Archives of biochemistry and biophysics, 2020, 08-15, Volume: 689

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition; Diet, High-Fat; Enzyme Inhibitors; Female; Obesity; Oxidative Stress; PCSK9 Inhibitors; Proprotein Convertase 9; Rats

2020
PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
    European journal of pharmacology, 2020, Sep-15, Volume: 883

    Topics: Animals; Apoptosis; Atorvastatin; Calcium Signaling; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Mitochondria, Heart; Myocytes, Cardiac; Obesity; PCSK9 Inhibitors; Proprotein Convertase 9; Rats, Wistar; Recovery of Function; Serine Proteinase Inhibitors; Ventricular Function, Left

2020
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
    Toxicology and applied pharmacology, 2020, 09-01, Volume: 402

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combination; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Random Allocation; Ventricular Dysfunction, Left; Vitamin B Complex

2020
Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected.
    Scientific reports, 2021, 01-26, Volume: 11, Issue:1

    Topics: Animals; Atorvastatin; Biomarkers; Cell Respiration; Citrate (si)-Synthase; Hydrogen Peroxide; Male; Metabolome; Mitochondria, Heart; Mitochondria, Liver; Mitochondria, Muscle; Obesity; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Swine; Swine, Miniature; Ubiquinone

2021
Effect of Nigella sativa, atorvastatin, or L-Carnitine on high fat diet-induced obesity in adult male Albino rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 141

    Topics: Animals; Anti-Obesity Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Body Weight; Carnitine; Diet, High-Fat; Fatty Liver; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nigella sativa; Obesity; Plant Extracts; Rats; Rats, Wistar

2021
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
    Journal of pharmaceutical and biomedical analysis, 2019, Feb-05, Volume: 164

    Topics: Adult; Atherosclerosis; Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Female; Gastric Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Postoperative Period; Preoperative Period; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Tandem Mass Spectrometry

2019
Clinical features related to statin-associated muscle symptoms.
    Muscle & nerve, 2019, Volume: 59, Issue:5

    Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People

2019
Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation.
    Neurochemical research, 2019, Volume: 44, Issue:5

    Topics: Animals; Antioxidants; Atorvastatin; Body Weight; Cognition; Cognitive Dysfunction; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice, Inbred C57BL; Obesity; Oxidative Stress; Sirtuin 1

2019
Comparison of metabolic profile of obese non-diabetic patients with coronary artery disease depending on atorvastatin dose.
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Volume: 72, Issue:5 cz 1

    Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Metabolome; Obesity; Ukraine

2019
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Current medical research and opinion, 2014, Volume: 30, Issue:2

    Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides

2014
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones

2014
Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress.
    Lipids in health and disease, 2014, Jun-21, Volume: 13

    Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Cell Survival; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Heptanoic Acids; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrroles; Real-Time Polymerase Chain Reaction

2014
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, May-20, Volume: 21

    Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking

2015
Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity.
    British journal of pharmacology, 2015, Volume: 172, Issue:20

    Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cell Line, Tumor; Citrulline; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Sucrose; Disease Models, Animal; Drug Therapy, Combination; Glucose; Homeostasis; Humans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; Sterol Regulatory Element Binding Protein 1

2015
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2016, Volume: 124, Issue:4

    Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Overweight; rho-Associated Kinases; Treatment Outcome

2016
Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.
    Diabetes, 2017, Volume: 66, Issue:2

    Topics: Adult; Aged; Animals; Antagomirs; Atorvastatin; Blotting, Northern; Carrier Proteins; Complement Factor H; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycoproteins; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Male; Mass Spectrometry; Metabolic Syndrome; Mice; MicroRNAs; Middle Aged; Multivariate Analysis; Obesity; Oligonucleotides; Prevalence; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Serum Albumin; Serum Albumin, Human

2017
Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E
    Microbiome, 2017, 03-13, Volume: 5, Issue:1

    Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics

2017
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
    Metabolism: clinical and experimental, 2010, Volume: 59, Issue:3

    Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Blood Glucose; Cytokines; Enzyme-Linked Immunosorbent Assay; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Immunohistochemistry; Insulin Resistance; Lipids; Male; Mice; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium Glutamate

2010
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
    Acta pharmacologica Sinica, 2010, Volume: 31, Issue:1

    Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate

2010
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
    Journal of hepatology, 2011, Volume: 54, Issue:5

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury

2011
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha

2011
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:8

    Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4

2012
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
    Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha

2013
Enhancing organ pool by statins: is this the future?
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:8

    Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4

2012
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
    European journal of clinical investigation, 2012, Volume: 42, Issue:12

    Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color

2012
[Atorvastatin and oxidative stress in coronary heart disease with obesity].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles

2012
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
    Clinical pharmacology and therapeutics, 2013, Volume: 93, Issue:3

    Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Mass Index; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Obesity; Organic Anion Transporters; Pyrroles

2013
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
    Japanese heart journal, 2004, Volume: 45, Issue:6

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Diet, Fat-Restricted; Drug Administration Schedule; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Pyrroles; Risk Factors; Smoking; Tissue Plasminogen Activator; Triglycerides

2004
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    American journal of hypertension, 2005, Volume: 18, Issue:4 Pt 1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines

2005
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
    Diabetologia, 2006, Volume: 49, Issue:8

    Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction

2006
Diabetes and residual risk of coronary heart disease.
    Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin

2007
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
    Revue medicale de Liege, 2007, Volume: 62, Issue:4

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States

2007
Metabolic syndrome with early aortic atherosclerosis in a child.
    Journal of the cardiometabolic syndrome, 2006,Summer, Volume: 1, Issue:4

    Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides

2006
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
    Pharmacological research, 2008, Volume: 57, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome

2008
Statins, leptin and regulatory T cells.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:6

    Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness

2008